Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 10/20 | 0.97 |
| ▸ | HTT | P42858 | 5/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.84 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.84 |
| ▸ | TSHR | P16473 | 5/20 | 0.84 |
| ▸ | MEN1 | O00255 | 4/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.84 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.84 |
| ▸ | MITF | O75030 | 1/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.82 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.82 |
| ▸ | GAA | P10253 | 2/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | IDE | P14735 | 1/20 | 0.67 |
| ▸ | XBP1 | P17861 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29445223 | 0.99 | LMNA (1.00) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| Bromide SCHEMBL940477 | 0.99 | SLC5A2 (0.97) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL13332637 | 0.93 | SLC5A2 (0.86) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL2494794 | 0.93 | LMNA (0.98) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL2474484 | 0.93 | LMNA (0.98) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL2496035 | 0.93 | LMNA (0.89) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL14847726 | 0.93 | SLC5A2 (0.86) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL2496102 | 0.92 | LMNA (0.98) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL2497664 | 0.92 | LMNA (0.98) | SLC5A2LMNAHTTALOX15HSD17B10 | |
| SCHEMBL2495262 | 0.89 | LMNA (0.91) | SLC5A2LMNAHTTALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | claimed |
| EP-2373629-B1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-04-10 | — | — | EP | claimed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| EP-2373629-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-12 | — | — | EP | claimed |
| WO-2010067067-A1 | COMPOUNDS FOR TREATING CANCER | EVOTEC AG (DE) | 2010-06-17 | — | — | WO | claimed |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-8871794-B2 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871794-B2 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-28 | — | — | US | disclosed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-20110166181-A1 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | TAKTIX CORPORATION | 2011-07-07 | — | — | US | disclosed |
| US-20110166181-A1 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | TAKTIX CORPORATION | 2011-07-07 | — | — | US | disclosed |
| US-7868028-B2 | Guanidine compounds as anesthetics and for treatment of nervous system disorders | Drasner, Fred (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868028-B2 | Guanidine compounds as anesthetics and for treatment of nervous system disorders | Drasner, Fred (US) | 2011-01-11 | — | — | US | disclosed |
| WO-2010067067-A1 | COMPOUNDS FOR TREATING CANCER | EVOTEC AG (DE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067067-A1 | COMPOUNDS FOR TREATING CANCER | EVOTEC AG (DE) | 2010-06-17 | — | — | WO | disclosed |
| US-20100150840-A1 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-17 | — | — | US | disclosed |
| US-20100150840-A1 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | SLC5A2 4162/4885LMNA 886/4885HTT 356/4885 |
| US-20100150840-A1 | Small-molecule agonists for type-2 orexin receptor | HCRTR2, HCRTR1, OXTR | SLC5A2 1397/4885LMNA 2921/4885HTT 988/4885 |
| US-20110166181-A1 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | CACNA1E, GRIA4, GRIA3 | SLC5A2 1700/4885LMNA 1775/4885HTT 1558/4885 |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BCL2, BAX, BCL2A1 | SLC5A2 2332/4885LMNA 2691/4885HTT 3022/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | SLC5A2 4703/4885LMNA 358/4885HTT 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.